Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price was down 5% during mid-day trading on Tuesday . The company traded as low as $4.73 and last traded at $4.74, with a volume of 2,805,878 shares. The stock had previously closed at $4.99.

A number of equities analysts recently issued reports on ZIOP shares. Griffin Securities reissued a “buy” rating and issued a $21.00 price objective on shares of Ziopharm Oncology in a report on Friday, July 1st. Vetr lowered Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price objective for the company. in a report on Monday, April 18th. Zacks Investment Research raised Ziopharm Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Raymond James Financial Inc. started coverage on Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating for the company. Finally, Mizuho increased their price objective on Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.57.

The stock’s 50-day moving average price is $6.21 and its 200 day moving average price is $6.94. The stock’s market capitalization is $597.69 million.

Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $1.89 million. During the same period last year, the company posted ($0.69) EPS. The firm’s revenue for the quarter was up 623.9% on a year-over-year basis. On average, equities research analysts predict that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

A number of hedge funds and institutional investors have made changes to their positions in the company. Morgan Stanley boosted its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares in the last quarter. Swiss National Bank boosted its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares in the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.